



OPEN ACCESS

EDITED AND REVIEWED BY
Andreas Recke,
University of Lübeck, Germany

*CORRESPONDENCE
Peiguang Wang
✉ wpg2370@163.com
Sen Yang
✉ yang2004sen@163.com

†These authors have contributed
equally to this work

SPECIALTY SECTION
This article was submitted to
Dermatology,
a section of the journal
Frontiers in Medicine

RECEIVED 23 November 2022
ACCEPTED 30 November 2022
PUBLISHED 12 December 2022

CITATION
Dai Y, Zheng X, Zhang Q, Hu X, Wang P
and Yang S (2022) Corrigendum: Case
report: Challenges in the diagnosis of a
case of Mal de Meleda and a
therapeutic attempt of ixekizumab and
Adalimumab. *Front. Med.* 9:1106530.
doi: 10.3389/fmed.2022.1106530

COPYRIGHT
© 2022 Dai, Zheng, Zhang, Hu, Wang
and Yang. This is an open-access
article distributed under the terms of
the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution
or reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Case report: Challenges in the diagnosis of a case of Mal de Meleda and a therapeutic attempt of ixekizumab and Adalimumab

Yuwei Dai^{1,2,3,4,5†}, Xiaodong Zheng^{1,2,3,4†}, Qi Zhang^{1,2,3,4,5},
Xia Hu^{1,2,3,4,5}, Peiguang Wang^{1,2,3,4*} and Sen Yang^{1,2,3,4,5*}

¹Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, China, ²Institute of Dermatology, Anhui Medical University, Hefei, China, ³Key Laboratory of Dermatology, Anhui Medical University, Ministry of Education, Hefei, China, ⁴Provincial Laboratory of Inflammatory and Immune Mediated Diseases, Hefei, China, ⁵Ferry Outpatient Department, The Ferry Skin Research Institute, Hefei, China

KEYWORDS

Mal de Meleda, MDM, Exomiser, HPO terms, Ixekizumab, Adalimumab

A corrigendum on

Case report: Challenges in the diagnosis of a case of Mal de Meleda and a therapeutic attempt of ixekizumab and Adalimumab

by Dai, Y., Zheng, X., Zhang, Q., Hu, X., Wang, P., and Yang, S. (2022). *Front. Med.* 9:821301. doi: 10.3389/fmed.2022.821301

In the published article, there was an error in the dosage of adalimumab. A correction has been made to **Report**, 1. This sentence previously stated:

“One month later, Adalimumab with dose of 300 mg was given subcutaneously.”

The corrected sentence appears below:

“One month later, Adalimumab with dose of 40 mg was given subcutaneously.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.